Skip to main content
Premium Trial:

Request an Annual Quote

Consumer Genomics in the Big Apple

Go ahead and get jealous of GTO. After all, we're based in New York City, and that happens to be where Navigenics is launching its personal genomics service next month, according to Steve Murphy at the Gene Sherpa blog. Murphy posts an e-mail he received from the company advertising its "Navigenics Health Compass" service, which "tests for genetic risk markers for 18 actionable common conditions -- cardiac disease, several cancers, Alzheimer’s among them," according to the blog. Check out the official invitation here. GTO hasn't gotten one yet, but you can bet we'll be camped out on a Soho doorstep come April.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.